▸ The full interactive deep dive — interactive price chart (updated weekly), scores, fair value, and the expert-claim panel: research.synthosresearch.com/TVTX

Theme: Genomics/biotech (rare kidney disease) Date: 2026-07-02

1. What It Is

Travere Therapeutics (formerly Retrophin) is a San Diego-based biopharmaceutical company focused on rare kidney diseases. Its lead growth product is Filspari (sparsentan), approved for IgA nephropathy (FSGS indication pending/expanding), alongside legacy rare-disease products Chenodal, Cholbam, and Thiola.

2. The Exponential Thesis

Filspari's launch is driving a genuine revenue inflection in a orphan-disease market with limited competition (until recently, no other targeted oral non-immunosuppressive therapy for IgA nephropathy). Revenue grew from $109.5M (2022) → $145.2M (2023) → $233.2M (2024) → $490.7M (2025) — revenue more than doubled in the most recent year, reflecting Filspari's ramp plus label expansion. FMP forward estimates continue the trajectory: $697.8M (2026E) → $968.9M (2027E) → $1.77B (2030E). This is a credible orphan-drug S-curve (small, underserved patient population; label expansion into FSGS would add a second leg of growth) — the type of thesis where a first-in-class or best-in-class rare-disease drug can compound revenue quickly off a small base before decelerating as it saturates the diagnosed, treated population.

3. Financial Health

  • Revenue: $490.7M (2025), +110% YoY — the strongest growth print among the five names reviewed here.
  • Profitability: Still operating-loss making but narrowing fast: operating income -$62.8M (2025) vs. -$323.8M (2024) and -$388.1M (2023) — a dramatic improvement (~5x reduction in operating loss) as revenue scales against a largely fixed commercial infrastructure. Net income -$25.5M (2025), also much improved from -$321.5M (2024).
  • Balance sheet: Cash $93.0M + short-term investments $229.8M = ~$323M liquid; total debt $328.7M (roughly matches liquid assets — leveraged balance sheet); equity only $114.8M (thin, though improving from $59.1M in 2024). Current ratio 2.7x, adequate near-term liquidity.
  • Cash flow: Operating cash flow turned positive for the first time: +$37.8M (2025) vs. -$237.5M (2024) and -$280.0M (2023) — a real inflection, though capex (-$58.2M) still pushes FCF negative (-$20.4M). This is the clearest "approaching self-funding" signal among the names in this batch.

4. Competitive Position / Moat

Filspari holds a differentiated position as an oral, dual endothelin/angiotensin receptor antagonist for IgA nephropathy — a genuine mechanism-of-action edge versus older immunosuppressive approaches, with FDA orphan-drug-type exclusivity protections. The rare-kidney-disease niche is less crowded than oncology or MS, giving Travere more room to run without giant-pharma competition, though newer entrants (e.g., additional IgAN therapies in development industry-wide) could erode the window over time.

5. Valuation

P/S ~6.9x, EV/EBITDA is extreme at ~164x (reflecting still-thin EBITDA), trailing P/E is negative (-68.2x, i.e., money-losing on a trailing basis), and the screen shows PEG of -0.55 — a negative PEG typically signals the P/E itself is negative (loss-making), which is the case here; it is not a meaningful "cheap" signal and should not be read as attractive value the way a normal positive-and-low PEG would be. On a P/S basis, 6.9x against 110% revenue growth (~0.06 "PSG" if analogous logic is applied) is not expensive for the growth rate — the more useful lens here is P/S-vs-growth given the company isn't GAAP profitable yet. Fair-value stance: reasonable-to-cheap on a sales-growth basis, but the negative PEG in the screen is a metric artifact of unprofitability, not a genuine value signal, and should be treated with caution.

6. What the Panel Says

Zero KB hits for "TVTX" or "Travere." As with TGTX, the screen's "conviction 12.1 (49 claims)" is a shared "biotech/genomics" bucket artifact — none of those 49 claims name Travere, Filspari, or sparsentan. This is a confirmed false KB match; there is no genuine panel view on this specific company in the current knowledge base.

7. Key Risks

  1. Concentration in a single growth product: Filspari drives essentially all incremental growth; any safety signal, reimbursement pushback, or competitive launch in IgAN would disproportionately hit the thesis.
  2. Leveraged balance sheet: Debt ($328.7M) roughly matches liquid assets, and equity is thin ($114.8M) — leaves less cushion than peers if the ramp stalls.
  3. Negative PEG / immature profitability: Not yet GAAP profitable on a trailing basis, so standard valuation multiples (P/E, PEG) are not usable as displayed; true valuation support depends on continued execution toward profitability.

8. Verdict

WATCH (leaning constructive given the clean revenue/cash-flow inflection). One-line thesis: Genuine, accelerating orphan-drug revenue ramp (Filspari in IgA nephropathy) with the cash-flow profile turning the corner — the most credible operational inflection of the three "shared-bucket" biotech names in this batch — but concentrated in one product with a leveraged balance sheet. Valuation stance: Fair-to-cheap on a sales-growth basis; the screen's negative PEG (-0.55) is a metric artifact of pre-profitability, not a real value signal. Biggest risk: Single-product (Filspari) concentration risk on a still-leveraged balance sheet. DATA FLAG: Zero genuine KB/panel coverage — the "conviction 12.1 (49 claims)" figure is a shared biotech/genomics bucket, not TVTX-specific commentary. Also, PEG of -0.55 reflects negative trailing EPS, not a genuine "cheap" signal — treat as not meaningful rather than bullish.